{
    "body": "What is dovitinib?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23228017", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24908540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21521775", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23443805", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24495750", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21976540", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25023489", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22180308", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24238094", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23010851", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23339124", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26070683", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23041231", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23400739", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24448819", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22230479", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24556040"
    ], 
    "ideal_answer": [
        "Dovitinib (TKI258) is a tyrosine kinase receptor inhibitor with potent activity against fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR)."
    ], 
    "exact_answer": [
        "tyrosine kinase receptor inhibitor"
    ], 
    "type": "factoid", 
    "id": "56d04a533975bb303a000010", 
    "snippets": [
        {
            "offsetInBeginSection": 12, 
            "offsetInEndSection": 312, 
            "text": "This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a receptor tyrosine kinase inhibitor with potent activity against fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR), in locally advanced or metastatic thyroid cancer patients", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26070683", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 151, 
            "text": "Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010851", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 166, 
            "text": "Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21976540", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 126, 
            "text": "Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23339124", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 98, 
            "text": "The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23041231", 
            "endSection": "title"
        }
    ]
}